Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2021 May;20(3):399-401.
doi: 10.1016/j.jcf.2020.12.011. Epub 2021 Jan 19.

Elexacafator/tezacaftor/ivacaftor resolves subfertility in females with CF: A two center case series

Kate E O'Connor  1 , Dana L Goodwin  1 , Andrew NeSmith  1 , Bryan Garcia  2 , Christina Mingora  2 , Sigrid L Ladores  1 , Steve M Rowe  1 , Stefanie Krick  1 , George M Solomon  3
Affiliations
Multicenter Study

Elexacafator/tezacaftor/ivacaftor resolves subfertility in females with CF: A two center case series

Kate E O'Connor et al. J Cyst Fibros. 2021 May.

Abstract

Infertility and subfertility are commonly faced by females with cystic fibrosis (FwCF) and resulting in decreased contraceptive use and increased utilization of reproductive technologies. Elexacaftor-tezacaftor-ivacaftor (ETI) is a CFTR modulator that affects common causes of subfertility. Two CF centers conducted a retrospective chart review on females with CF who were receiving ETI and became pregnant. We analyzed obstetrical-gynecological history, genotype, and clinical response to ETI therapy. Fourteen FwCF on ETI became pregnant. Half (7) of the FwCFs were previously attempting to conceive, but only three were using contraceptives. Four FwCF had a history of infertility; two were reconsidering use of reproductive technologies (IUI). Patients achieved conception at mean 8 weeks after initiating ETI. ETI may lessen CF-associated factors that affect fertility; however, its exact mechanism is unknown. This warrants counseling on contraceptive use and family planning prior to initiation of therapy and at routine intervals while utilizing ETI.

Keywords: CFTR modulators; Cystic fibrosis; Fertility.

PubMed Disclaimer

Conflict of interest statement

Declarations of Competing Interest None

References

    1. Hughan K, Daley T, Rayas M, Kelly A, Roe A. Female reproductive health in cystic fibrosis. J Cyst Fibros 2019;18:S95–S104. doi: 10.1016/j.jcf.2019.08.024. - DOI - PubMed
    1. Shteinberg M, Lulu A, Downey D, Blumenfeld Z, Rousset-Jablonski C, Perceval M, et al. Failure to conceive in women with CF Is associated with pancreatic insufficiency and advancing age. J Cyst Fibros 2019;18:525–9. doi: 10.1016/j.jcf.2018.10.009. - DOI - PubMed
    1. Tournier A, Murris M, Prevotat A, Fanton A, Bettiol C, Parinaud J. Fertility of women with cystic fibrosis: a French survey. Reprod Biomed Online 2019;39.3:492–5. doi: 10.1016/j.rbmo.2019.04.128. - DOI - PubMed
    1. Vanwort T, Lee J, Karvir H, Whitehouse M, Beim P, Copperman A. Female cystic fibrosis mutation carriers and assisted reproductive technology: does carrier status affect reproductive outcomes. Fertil Steril 2014;102.5:1324–30. doi: 10.1016/j.fertnstert.2014.07.1234. - DOI - PubMed
    1. Middleton P, Mall M, Drevinek P, Lands L, McKone E, Polineni D, et al. Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del al-lele. N Engl J Med 2019;381.19:1809–19. doi: 10.1056/nejmoa1908639. - DOI - PMC - PubMed

Publication types